These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26614643)

  • 1. Long-term infliximab therapy is needed for sustained steroid-free remission in patients with ulcerative colitis.
    Le Roy F; Siproudhis L; Bretagne JF; Bouguen G
    Dig Liver Dis; 2016 Feb; 48(2):208-9. PubMed ID: 26614643
    [No Abstract]   [Full Text] [Related]  

  • 2. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids.
    Garcia-Planella E; Mañosa M; Van Domselaar M; Gordillo J; Zabana Y; Cabré E; López San Román A; Domènech E
    Dig Liver Dis; 2012 Mar; 44(3):206-10. PubMed ID: 22079262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
    Taxonera C; Barreiro-de Acosta M; Calvo M; Saro C; Bastida G; Martín-Arranz MD; Gisbert JP; García-Sánchez V; Marín-Jiménez I; Bermejo F; Chaparro M; Ponferrada Á; Martínez-Montiel MP; Pajares R; de Gracia C; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
    Dig Dis Sci; 2015 Oct; 60(10):3075-84. PubMed ID: 26044830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis.
    Murthy SK; Greenberg GR; Croitoru K; Nguyen GC; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2015 Sep; 21(9):2090-6. PubMed ID: 26099066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.
    Filippi J; Laharie D; Michiels C; Flamand M; Bouguen G; Nancey S; Presles E; Paul S; Schneider S; Hébuterne X; Roblin X
    J Crohns Colitis; 2015 Mar; 9(3):252-8. PubMed ID: 25588386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
    Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower Dose Infliximab for Ulcerative Colitis: How Low Can We Go and How Much Can be Saved?
    Christophi GP; Ciorba MA
    J Clin Gastroenterol; 2015 Aug; 49(7):539-40. PubMed ID: 26057322
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis.
    Jiang XL; Cui HF; Gao J; Fan H
    J Clin Gastroenterol; 2015 Aug; 49(7):582-8. PubMed ID: 25844841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy.
    Farkas K; Lakatos PL; Nagy F; Szepes Z; Miheller P; Papp M; Palatka K; Bálint A; Bor R; Wittmann T; Molnár T
    Scand J Gastroenterol; 2013 Dec; 48(12):1394-8. PubMed ID: 24131338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
    Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
    Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
    Mocciaro F; Orlando A; Scimeca D; Cottone M
    Recenti Prog Med; 2007 Nov; 98(11):560-4. PubMed ID: 18044405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
    Lichtenstein GR; Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP
    Dig Dis Sci; 2016 Jan; 61(1):221-9. PubMed ID: 26563167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
    Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimising infliximab induction dosing for patients with ulcerative colitis.
    Dreesen E; Faelens R; Van Assche G; Ferrante M; Vermeire S; Gils A; Bouillon T
    Br J Clin Pharmacol; 2019 Apr; 85(4):782-795. PubMed ID: 30634202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term infliximab therapy for ulcerative colitis in real clinical practice].
    Knyazev OV; Parfenov AI; Kagramanova AV; Ruchkina IN; Shcherbakov PL; Shakhpazyan NK; Noskova KK; Ivkina TI; Khomeriki SG
    Ter Arkh; 2016; 88(8):46-52. PubMed ID: 27636927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids.
    Bello C; Belaiche J; Louis E; Reenaers C
    J Crohns Colitis; 2011 Jun; 5(3):196-202. PubMed ID: 21575881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.